History & Locations
Focused on overcoming the challenges of conventional glaucoma therapies, Glaukos pioneered micro-invasive glaucoma surgery, or MIGS. In 2012, Glaukos launched the first-ever US-approved MIGS device, the iStent® Trabecular Micro-Bypass Stent. Glaukos launched its next-generation iStent inject® device in the United States in 2018. In addition to an abiding focus on glaucoma, Glaukos is broadening its mission to include new aspirations that seek to improve treatment alternatives and quality of life for people suffering with corneal disorders and retinal diseases. Glaukos is seeking to leverage its platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease. Learn more about our history and international presence.
More About Our History & Locations